Drugs / Adult human mesenchymal stem cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06893250 Comparator | Sep 2024 → Dec 2027 expected | osteoarthritis, knee | University Hospital of North Norway | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adult human mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06893250 ↗ |
| Known as | ADSTEM Inj. | “ADSTEM Inj. (Adult human mesenchymal stem cells)” NCT06893250 ↗ |
| Modality | Cell therapy | “Adipose tissue stem cells, from abdominal fat.” NCT06893250 ↗ |